Список литературы

1. Voulgaridou A., Kalfa T.A. Autoimmune Hemolytic Anemia in the Pediatric Setting. J.Clin. Med. 2021; 10: 216. doi: 0.3390/jcm10020216.

2. Hill Q.A., Hill A., Berentsen S. Defining autoimmune hemolytic anemia: A systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019; 3: 1897-906. doi: 10.1182/bloodadvances.2019000036.

3. Aladjidi N. et al. New insights into childhood autoimmune hemolytic anemia: A French national observational study of 265 children. Haematologica. 2011; 96: 655-63.

4. Despotovic J. M. Diagnosis and management of autoimmune cytopenias. Springer. 2018.

5. Barcellini W. New insights in the pathogenesis of AIHA. Transfus Med Hemother. 2015; 42: 287-93.

6. Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev. 2008; 22: 17 - 31.

7. Kalfa T.A. Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Progr. 2016; 2: 690-7.

8. Zeerleder S. Autoimmune haemolytic anaemia - a practical guide to cope with a diagnostic and therapeutic challenge. Neth J Med. 2011; 69: 177-84.

9. Bass G.F., Tuscano E.T. Diagnosis and classification of autoimmune hemolytic anemia. Autoiimmune Rev. 2014; 13: 560-4.

10. Garratty G. Drug-induced immune hemolytic anemia. Hematology American Society of Hematology Education Program. 2009; 73-9.

11. Aladjidi, N. et al. Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatr. Blood Cancer. 2017; 64: e26683. doi: 10.1002/pbc.26683.

12. Berensten S., Sundic T. Red Blood Cell Destruction in Autoimmune Hemolytic Anemia: Role of Complement and Potential New Targets for Therapy. Hindawi Publishing Corporation BioMed Research International. 2015; article ID 363278, 11 pages. doi: 10.1155/2015/363278.

13. Berentsen S. How I manage patients with cold agglutinin disease. Br. J. Haematol. 2018; 181: 320-30.

14. Singh A., Mandal A., Patel A., Mishra S. Autoimmune Haemolytic Anaemia - A Spectrum of Presentation in Children. J. Clin. Diagn. Res. 2017; 11: SR01-SR02.

15. Lee S.C., Youn Y.S., Rhim J.W., Kang J.H., Lee K.Y. Early Serologic Diagnosis of Mycoplasma pneumoniae Pneumonia: An Observational Study on Changes in Titers of Specific-IgM Antibodies and Cold Agglutinins. Medicine. 2016; 95: e3605.

16. Jeremy W. J. et al. Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review. Blood Advances First Edition. 2023; 11(7): 2520-7. doi: 10.1182/bloodadvances.2022009516.

17. Donath J.L., Landsteiner K. Uber paroxysmale haemoglobinurie. Munch Med Wochenschr. 1904; 51: 1590-3.

18. Ladogana S. et al. Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association. Blood Transfus. 2017; 15: 259-67. doi: 10.2450/2016.0072-16.

19. Lau P., Haesler W.E., Wurzel H.A. Positive direct antiglobulin reaction in a patient population. Am J Clin Pathol. 1976; 65(3): 368-75.

20. Alam M.M. Autoimmune Hemolytic Anemia in Children: Diagnostic Approach and Management. IJR2H, 5(2): 150 - 160, 2022; Article no.IJR2H.89337.

21. Teachey, D.T., Lambert M.P. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr. Clin. N. Am. 2013; 60: 1489-511.

22. U. et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Reviews. 2019. doi: 10.1016/j.blre.2019.100648.

23. Weli M. et al. Diagnosis and management of autoimmune hemolytic anemia in children. Transfus. Clin. Biol. 2020; 27: 61-4.

24. Miano M. How I manage Evans syndrome and AIHA cases in children. Br J Haematol. 2016; 172: 524-34. doi: 10.1111/bjh.13866.

25. Zanella A., Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014; 99: 1547-54.

26. Ladogana S. et al. Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP). Blood Transfus. 2018; 16: 352-8. doi: 10.2450/2018.0024-18.

27. Zecca M. et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003; 101: 3857 - 3861.

28. Howard J., Hoffbrand A.V., Prentice H.G., Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and autoimmune thrombocytopenia purpura. Br J Haematol. 2002; 117(3): 712-5.

29. Kotb R. et al. Efficacy of mycophenolate mofetil in adult refractory autoimmune cytopenias: a single center preliminary study. Eur J Haematol. 2005; 75(1): 60-4.

30. Miano M. et al. Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune cytopenias: a single centre experience. Br J Haematol. 2015; 171(2): 247-53. doi: 10.1111/bjh.13533.

31. Panigrahi A., Clark A., Myers J., Raj A. A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias. Pediatr Blood Cancer. 2017; 64: 287-93. doi: 10.1002/pbc.26210.

32. Barcellini W., Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front. Immunol. 2020; 11: 946.

33. Miano M. et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian Association of Paediatric Haematology and Oncology. Br J Haematol. 2016; 175: 490-5. doi: 10.1111/bjh.14261.

34. Berrueco R. et al. Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity. Front. Pediatr. 2023; 11: 1174671. doi: 10.3389/fped.2023.1174671.

35. Abdelwahab O.A. et al. Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta analysis. Clinical Rheumatology. 2024; 43: 621-32. doi: 10.1007/s10067-023-06820-4.

36. Zhuxin Zhang et al. Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study. Annals of Medicine. 2023; 55(2): 2282180. doi: 10.1080/07853890.2023.2282180.

37. Bride K.L. et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: Results of a prospective multi-institutional trial. Blood. 2016; 127: 17 - 28.

38. Thabet A.F., Faisal M. Pulse Cyclophosphamide Therapy in Refractory Warm Autoimmune Hemolytic Anemia: A New Perspective. Indian J Hematol Blood Transfus. 2014; 30(4): 313-8. doi: 10.1007/s12288-013-0290-z.

39. Леонтьева М.Е., Деордиева Е.А., Солопова Г.Г., Никонова Е.С., Щербина А.Ю. Профилактика развития тяжелых инфекционных осложнений у пациентов с асплений и гипоспленией. Педиатрия им. Г.Н. Сперанского. 2023; 102 (2): 89 - 99. doi: 10.24110/0031-403X-2023-102-2-89-99.

40. Cvetkovic, Z. et al. The Role of the Spleen and the Place of Splenectomy in Autoimmune Hemolytic Anemia - A Review of Current Knowledge. Diagnostics. 2023; 13: 2891. doi: 10.3390/diagnostics13182891.

41. Приказ Министерства здравоохранения РФ от 20 октября 2020 г. N 1134н "Об утверждении порядка медицинского обследования реципиента, проведения проб на индивидуальную совместимость, включая биологическую пробу, при трансфузии донорской крови и (или) ее компонентов".

42. Володин Н.Н. Стратегия медико-психолого-социальной реабилитации детей с гематологическими и онкологическими заболеваниями. Онкогематология. 2015; 1: 7 - 15.

43. Приказ Министерства здравоохранения РФ от 10 июня 2021 г. N 629н "Об утверждении Порядка диспансерного наблюдения детей с онкологическими и гематологическими заболеваниями".

44. Медицинские противопоказания к проведению профилактических прививок препаратами национального календаря прививок: Методические указания. - М.: Федеральный центр госсанэпиднадзора Минздрава России, 2002. - 16 с.

45. Bride K., Teachey D. Autoimmune lymphoproliferative syndrome: More than a FAScinating disease. F1000 Res. 2017; 6: 1928.

46. Teachey D.T., Seif A.E., Grupp S.A. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol. 2010; 148: 205-16.

47. Oliveira J.B. al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010; 116(14): e35 - 40.

48. Rao V.K., Oliveira J.B. How I treat autoimmune lymphoproliferative syndrome. Blood. 2011; 118(22): 5741-51.

49. Rao V.K. et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009; 52(7): 847-52.

50. Gathmann B. et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014; 134(1): 116-26.

51. Gobert D. et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011; 155(4): 498 - 508.

52. Schubert D. et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014; 20: 1410-6.

53. Lo B. et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015; 349: 436-40.

54. Dall'Era M., Davis J. CTLA4Ig: A novel inhibitor of costimulation. Lupus. 2004; 13: 372-76.

55. Hess J. et al. Successful treatment of severe refractory autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept. Transfusion. 2018; 58: 2122-7.

56. Bader-Meunier B. et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr. 2005; 146(5): 648-53.

57. Gomard-Mennesson E. et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006; 15(4): 223-31.

58. Olfat M., Silverman E.D., Levy D.M. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015; 24(9): 966-72.

59. Alba P., Karim M.Y., Hunt B.J. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2003; 12(8): 633-5.

60. Mak A., Mok C.C. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus. 2005; 14(10): 856-8.

61. Bride K.L. et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016; 127(1): 17 - 28.

62. Maggiore G. T. et al. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: Long-term outcome in 16 children. J Pediatr. 2011; 159: 127-32.

63. Raj S., Stephen T., Debski R.F. Giant cell hepatitis with autoimmune hemolytic anemia: A case report and review of pediatric literature. Clin Pediatr. 2011; 50: 357-59.

64. Brichard B., Sokal E., Gosseye S., Buts J.P., Gadisseux J.F., Cornu G. Coombs-positive giant cell hepatitis of infancy: Effect of steroids and azathioprine therapy. Eur J Pediatr. 1991; 150: 314-17.

65. Bernard O., Hadchouel M., Scotto J., Odievre M., Alagille D. Severe giant cell hepatitis with autoimmune hemolytic anemia in early childhood. J Pediatr. 1981; 99: 704-11.

66. Shanbhag S.; Spivak J. Paroxysmal cold hemoglobinuria. Hematol Oncol Clin N Am. 2015; 29: 473-8.

67. Barcellini W, Fattizzo B. The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease. Expert Rev Hematol 2024; 17: 287-94.

68. Berentsen S. How I treat cold agglutinin disease. Blood 2021; 137: 1295-303.

69. Berentsen S. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103: 2925-8.

70. Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 2017; 130: 537-41.

71. Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda M, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018; 132: 547-50.

72. Jalink M, Berentsen S, Castillo JJ, Treon SP, Cruijsen M, Fattizzo B, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood 2021; 138: 2002-5.

73. Zaninoni A, Giannotta JA, Gall A, Artuso R, Bianchi P, Malcovati L, et al. The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. Front Immunol 2021; 12.

74. Mohamed A, Alkhatib M, Alshurafa A, El Omri H. Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature. Hematology 2023; 28.

75. Broome CM, Cunningham JM, Mullins M, Jiang X, Bylsma LC, Fryzek JP, et al. Increased risk of thrombotic events in cold agglutinin disease: A 10 year retrospective analysis. Res Pract Thromb Haemost 2020; 4: 628-35.

76. Аутоиммунные гемолитические анемии/Н.В. Цветаева, О.Ф. Никулина, В.Д. Латышев [и др.]//Алгоритмы диагностики и протоколы лечения заболеваний системы крови: В двух томах. - 2-е издание. - Москва: ООО "Издательский дом Практика", 2024. - С. 245 - 269.

77. Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2018 Nov 30; 2018(1): 382 - 389.

78. Giannotta JA, Fattizzo B, Cavallaro F, Barcellini W. Infectious Complications in Autoimmune Hemolytic Anemia. J Clin Med. 2021 Jan 5; 10(1): 164.

79. Berrueco R, Gonz lez-Forster E, Deya-Martinez A, Solsona M, Garc a-Garc a A, Calzada-Hern ndez J, Yiyi L, Vlagea A, Ruiz-Llobet A, Alsina L. Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity. Front Pediatr. 2023 Oct 17; 11: 1174671.

80. Borja-Montes OF, Toro-Pedroza A, Horton DD, Andritsos LA, Ebaid A. Mycophenolate Mofetil for the Treatment of Warm Autoimmune Haemolytic Anaemia Post-Rituximab Therapy: A Case Series. Eur J Case Rep Intern Med. 2024 Aug 14; 11(9): 004780.

81. Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, Houghton S, Jayne DRW. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease. Front Immunol. 2021 May 12; 12: 671503.

82. Quartier P. et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab//The Lancet. - 2001. - Т. 358. - N 9292. - С. 1511 - 1513.

83. Tahra S. K. et al. Hypogammaglobulinemia and severe infection risk in patients with autoimmune diseases during rituximab treatment//Journal of Turkish Society for Rheumatology. - 2023.

84. Christou E. A. A. et al. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab//International Reviews of Immunology. - 2017. - Т. 36. - N 6. - С. 352 - 359.